Company Shares of TherapeuticsMD Drops by -4.77%

TherapeuticsMD (NYSEMKT:TXMD) has tumbled 4.77% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 2.69% in the last four weeks. The stocks have underperformed the S&P 500 by 3.62% during the past week but TherapeuticsMD (NYSEMKT:TXMD) it has outperformed the index in 4 weeks by 1.76%.

TherapeuticsMD (NYSEMKT:TXMD): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $8.24 and $8.13 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $8.54. The buying momentum continued till the end and the stock did not give up its gains. It closed at $8.39, notching a gain of 2.07% for the day. The total traded volume was 4,735,811 . The stock had closed at $8.22 on the previous day.

The company shares have rallied 4.61% from its 1 Year high price. On Dec 29, 2015, the shares registered one year high at $11.26 and the one year low was seen on Oct 22, 2015. The 50-Day Moving Average price is $8.36 and the 200 Day Moving Average price is recorded at $7.73.

On the companys insider trading activities, Collins Cooper C., director of Therapeuticsmd, Inc., executed a transaction worth $99,680 on March 11, 2016. A total of 16,000 shares were purchased at an average price of $6.23. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.

Many analysts have stated their opinion on the company shares. Goldman Sachs initiates coverage on TherapeuticsMD (NYSEMKT:TXMD) . The global brokerage major announces a current price target of $10 per share. Analysts at the Goldman Sachs have a current rating of Buy on the shares. The rating by the firm was issued on April 4, 2016. Currently the company Insiders own 26.04% of TherapeuticsMD shares according to the proxy statements. Institutional Investors own 77.7% of TherapeuticsMD shares. During last six month period, the net percent change held by insiders has seen a change of 80%.

TherapeuticsMD, Inc. is a womens health care product company. The Company is engaged in creating and commercializing products for women. The Company is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. It manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter (OTC) vitamins. It markets its prescription and OTC prenatal vitamins and other products under its vitaMedMD brand name and duplicate formulations of its prescription prenatal vitamin products, also referred to as generic formulations, under its BocaGreenMD brand name. The Companys products include prenatal vitamins, vitaMedMD Plus Rx, vitaMedMD One Rx, vitaMedMD RediChew Rx and BocaGreenMD Prena1 line of prescription prenatal vitamins, which included three prescription prenatal vitamins that were generic formulations of its vitaMedMD-branded prescription prenatal vitamins.

Leave a Reply

Davi Freedman - Is it time to Sell?

Top Brokerage Firms are advising their investors on Davi Freedman. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.